IMODE is organising its fourth annual convention during BioFIT with a morning of conferences and, if interested, participation in the BioFIT one-to-one meetings during the afternoon.

PROGRAMME | December 10th 


– Dr. Youness Karrout, University of Lille, France
“Hot melt extruded polysaccharide blends for controlled drug delivery”

– Natalia T. Correia, University of Lille, France
“Investigation of complex molecular dynamics in multi-component systems”

– Dr Sheng Qi, University of East Anglia, UK.
“3D printing of personalised pharmaceutical solid dosage form: promises and challenges”

– Dr Dennis Douroumis, University of Greenwich, UK
“Engineering of pharmaceutical cocrystals and salts:  State of the art industrial approaches”

– Dr Duncan Craig, University College London, UK


Registration to the IMODE convention is free but mandatory. It gives you a free access for the afternoon of the 10th of December at BioFIT.

By participating to IMODE convention, you obtain a 50% discount on your BioFIT pass for the day of December 11th. Please contact Ségolène Lebrun to obtain your coupon code.


IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).

The project’s overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

More information about IMODE:

IMODE partners: